The FASEB Journal, Vol 4, 3087-3098, Copyright © 1990 by The Federation of American Societies for Experimental Biology

REVIEWS

In vivo models of arterial thrombosis and thrombolysis

LR Bush and RJ Shebuski
Department of Cardiovascular Research, Hoffman-La Roche, Inc., Nutley, New Jersey 07110.

This year approximately 1.5 million Americans will undergo a myocardial infarction (MI). Of those who make it to the hospital (approximately 1.2 million), only about 20% will receive thrombolytic therapy. Multiple factors contribute to this dismaying figure, but most of them are risk/benefit-related. Moreover, of those receiving lytic therapy, the coronary arteries of as many as one-third may not reopen, and of those that do undergo coronary thrombolysis, an unacceptable fraction will experience reocclusion acutely. Thus, despite significant progress, major challenges for antithrombotic and thrombolytic therapy remain. Promising results with aspirin provide some hope that the figures above can be altered favorably. Efforts are under way in industry and academia to develop drugs to accomplish one or more of the following: lower the incidence of MI, prevent the development of unstable angina or retard its progression to frank MI, increase the inclusion window for lytic therapy, raise the percentage of patients undergoing successful thrombolysis, and maintain coronary patency. During the period that thrombolytic agents have come into vogue important advances have been made in our understanding of platelet function, coagulation, and the endogenous fibrinolytic system. These have spurred the development of novel drugs, such as platelet fibrinogen receptor antagonists, plasminogen activators, and inhibitors of factor IIa (thrombin) and XIIIa. Evaluation of these agents for their antithrombotic or profibrinolytic activity requires relevant animal models of thrombosis. Despite appropriate concerns about their clinical relevance, these models bridge the wide gap between test tube assays of aggregation or coagulation and humans.

This article has been cited by other articles:

				H. Li, S. Lockyer, A. Concepcion, X. Gong, H. Takizawa, M. Guertin, Y. Matsumoto, J. Kambayashi, N. N. Tandon, and Y. Liu The Fab Fragment of a Novel Anti-GPVI Monoclonal Antibody, OM4, Reduces In Vivo Thrombosis Without Bleeding Risk in Rats Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1199 - 1205. [Abstract] [Full Text] [PDF]

				H. Ikeda, T. Ueyama, T. Murohara, H. Yasukawa, N. Haramaki, H. Eguchi, A. Katoh, Y. Takajo, I. Onitsuka, T. Ueno, et al. Adhesive Interaction Between P-Selectin and Sialyl Lewisx Plays an Important Role in Recurrent Coronary Arterial Thrombosis in Dogs Arterioscler. Thromb. Vasc. Biol., April 1, 1999; 19(4): 1083 - 1090. [Abstract] [Full Text] [PDF]

				H. Eguchi, H. Ikeda, T. Murohara, H. Yasukawa, N. Haramaki, S. Sakisaka, and T. Imaizumi Endothelial Injuries of Coronary Arteries Distal to Thrombotic Sites : Role of Adhesive Interaction Between Endothelial P-Selectin and Leukocyte Sialyl LewisX Circ. Res., March 19, 1999; 84(5): 525 - 535. [Abstract] [Full Text] [PDF]

				J. D. Folts, A. I. Schafer, J. Loscalzo, J. T. Willerson, and J. E. Muller A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials J. Am. Coll. Cardiol., February 1, 1999; 33(2): 295 - 303. [Abstract] [Full Text] [PDF]

				A. Katoh, H. Ikeda, T. Murohara, N. Haramaki, H. Ito, and T. Imaizumi Platelet-Derived 12-Hydroxyeicosatetraenoic Acid Plays an Important Role in Mediating Canine Coronary Thrombosis by Regulating Platelet Glycoprotein IIb/IIIa Activation Circulation, December 22, 1998; 98(25): 2891 - 2898. [Abstract] [Full Text] [PDF]

				H. E. Osman, N. Maalej, D. Shanmuganayagam, and J. D. Folts Grape Juice but Not Orange or Grapefruit Juice Inhibits Platelet Activity in Dogs and Monkeys (Macaca fasciularis) J. Nutr., December 1, 1998; 128(12): 2307 - 2312. [Abstract] [Full Text]

				S. Pislaru, C. Pislaru, M. Szilard, J. Arnout, and F. Van de Werf In vivo effects of contrast media on coronary thrombolysis J. Am. Coll. Cardiol., October 1, 1998; 32(4): 1102 - 1108. [Abstract] [Full Text] [PDF]

				P. D Verdouw, M. A van den Doel, S. de Zeeuw, and D. J Duncker Animal models in the study of myocardial ischaemia and ischaemic syndromes Cardiovasc Res, July 1, 1998; 39(1): 121 - 135. [Full Text] [PDF]

				J. J. Cook, G. R. Sitko, B. Bednar, C. Condra, M. J. Mellott, D.-M. Feng, R. F. Nutt, J. A. Shafer, R. J. Gould, and T. M. Connolly An Antibody Against the Exosite of the Cloned Thrombin Receptor Inhibits Experimental Arterial Thrombosis in the African Green Monkey Circulation, June 15, 1995; 91(12): 2961 - 2971. [Abstract] [Full Text]

				H. Lin and D. B. Young Opposing Effects of Plasma Epinephrine and Norepinephrine on Coronary Thrombosis In Vivo Circulation, February 15, 1995; 91(4): 1135 - 1142. [Abstract] [Full Text]

				H. S. Demrow, P. R. Slane, and J. D. Folts Administration of Wine and Grape Juice Inhibits In Vivo Platelet Activity and Thrombosis in Stenosed Canine Coronary Arteries Circulation, February 15, 1995; 91(4): 1182 - 1188. [Abstract] [Full Text]

				R. Kornowski, M. Glikson, D. Ohad, N. Varda-Bloom, and A. Battler Electrical Injury in the Femoral Artery of Rabbits as a Model for Arterial Thrombosis: A Pilot Study Angiology, April 1, 1994; 45(4): 295 - 300. [Abstract] [PDF]